<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396520/" ref="ordinalpos=4292&amp;ncbi_uid=7433398&amp;link_uid=PMC4396520" image-link="/pmc/articles/PMC4396520/figure/f6-copd-10-715/" class="imagepopup">Figure 6.  From: Rosiglitazone attenuates the metalloprotease/anti-metalloprotease imbalance in emphysema induced by cigarette smoke: involvement of extracellular signal-regulated kinase and NFκB <span class="highlight" style="background-color:">signaling</span>. </a></div><br /><div class="p4l_captionBody">Effects of rosiglitazone on the signaling pathway of MAPK.<b>Notes:</b> The expression of P38, phospho-P38, ERK1/2, phospho-ERK1/2, JNK, and phospho-JNK was measured by Western blotting (<b>A</b>), and the target protein bands were densitometrically analyzed normalized to β-actin (<b>B</b>). *P&lt;0.05, compared with the control group; ▲P&lt;0.05, compared with the CS group.<b>Abbreviations:</b> MAPK, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinase-1 and -2; JNK, c-Jun N-terminal kinase; CS, cigarette smoke; RCS, rosiglitazone-cigarette smoke.</div></div>